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Summary. Defects of load-bearing connective tissues
such as articular cartilage, often result from trauma,
degenerative or age-related disease. Osteoarthritis (OA)
presents a major clinical challenge to clinicians due to
the limited inherent repair capacity of articular cartilage.
Articular cartilage defects are increasingly common
among the elderly population causing pain, reduced joint
function and significant disability among affected
patients. The poor capacity for self-repair of chondral
defects has resulted in the development of a large variety
of treatment approaches including Autologous
Chondrocyte Transplantation (ACT), microfracture and
mosaicplasty methods. In ACT, a cartilage biopsy is
taken from the patient and articular chondrocytes are
isolated. The cells are then expanded after several
passages in vitro and used to fill the cartilage defect.
Since its introduction, ACT has become a widely applied
surgical method with good to excellent clinical
outcomes. More recently, classical ACT has been
combined with tissue engineering and implantable
scaffolds for improved results. However, there are still
major problems associated with the ACT technique
which relate mainly to chondrocyte de-differentiation
during the expansion phase in monolayer culture and the
poor integration of the implants into the surrounding
cartilage tissue. Novel approaches using mesenchymal
stem cells (MSCs) as an alternative cell source to patient
derived chondrocytes are currently on trial. MSCs have
shown significant potential for chondrogenesis in animal
models. This review article discusses the potential of
MSCs in tissue engineering and regenerative medicine
and highlights their potential for cartilage repair and
cell-based therapies for osteoarthritis and a range of
related osteoarticular disorders.
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Introduction
Modern biomedical science has evolved at a
staggering pace over the last century, especially in the
last five decades. Significant advances have been made
in the prevention, diagnosis and treatment of a range of
infectious, neurodegenerative, cardiovascular,
respiratory, renal, hepatic and diabetic diseases. For the
past 160 years human life expectancy has increased by a
quarter of a year every year (Oeppen and Vaupel, 2002).
It is predicted that life expectancy will continue to
increase by 2.5 years each decade, meaning that the
western world's average life expectancy should reach
and exceed 100 within the next 50 years (Oeppen and
Vaupel, 2002). An important side-effect of such an
increased lifespan in humans is the mounting burden of
neoplastic, arthritic and rheumatic diseases. According
to the World Health Organization (WHO), rheumatic or
musculoskeletal conditions comprise over 150 diseases
and syndromes, which are usually progressive and
associated with pain. They can broadly be categorized as
joint diseases, physical disability, spinal disorders, and
conditions resulting from trauma. Musculoskeletal
conditions are leading causes of morbidity and disability,
giving rise to enormous healthcare expenditures and loss
of work. Knowledge of the key determinants of
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disability in musculoskeletal conditions is critical for
reducing their burden on the world's growing population
(Weigl et al., 2008). The number of rheumatoid arthritis
(RA) and osteoarthritis (OA) patients steadily rises as
the elderly population grows in Western Europe, North
America and the rest of the developing world. RA, OA
and back pain are important causes of disability-
adjusted-life years in both the developed and developing
world (Brooks, 2006). Back and knee pain are common
in the community and are likely to increase with the
ageing population (Brooks, 2006). Until recently OA
was viewed as a “degenerative” or “wear-and-tear”
disease and held little interest for most clinicians. In fact
rheumatologists refused to have it classified as one of
the conditions in their speciality until very recently.
Veterinarians took an interest in it only because they had
racehorses and racing greyhounds to take care of, whose
economic value to their owners and the racing industries
made it a worthwhile pursuit. Thus far human and
veterinary clinical medicine has had little to offer,
especially as OA was considered to be part of ageing and
few distinctions were made in the clinical presentations.
It is now generally accepted that OA must be viewed
not only as the final common pathway for ageing and
injuries of the joint but also as an active joint disease. As
the population of the world grows older and medical
advances lengthen average life expectancy, osteoarthritis
will become a larger public health problem - not because
it is a manifestation of ageing but because it usually
takes many years to reach clinical relevance.
Osteoarthritis is already one of the ten most disabling
diseases in developed countries.
The global pharmaceutical industries have been
ignorant about the emergence of OA as a major
musculoskeletal condition. They have in fact produced a
limited portfolio of drugs for the treatment of arthritic
conditions. However, the majority of the drugs they have
offered for the treatment of arthritic and rheumatic
diseases have been woefully inadequate as they only
treat the symptoms of pain and inflammation. Although
pharmaceutical companies have used a variety of
methods including high throughput screening and
combinatorial chemistry in their arthritis research
programmes, thus far, they have failed to produce a
single drug with the capacity to reverse the molecular
changes that occur in OA. Consequently more effective
function-modifying therapeutic strategies will need to be
introduced for the clinical treatment of arthritic diseases
such as OA. Connective tissue injuries are often very
painful and connected with loss of biomechanical
function, leading to restricted ability of patients to carry
on with their daily routines.
Bone and cartilage defects are common features of
joint diseases, such as rheumatoid arthritis and OA (Noel
et al., 2002). They have a significant social and
economic impact on the aging population. Despite
progress in orthopaedic surgery, bone and cartilage
repair is a major challenge as large defects will not
spontaneously heal (Noel et al., 2002). Regenerative
medicine is an emerging field that seeks to repair or
replace injured tissues and organs through natural or
bioengineered means. Recent research on stromal
mesenchymal stem cells (MSCs) has provided a new and
exciting opportunity for bone and cartilage tissue
engineering. Thus far, MSCs have been isolated from
bone marrow, periosteum, trabecular bone, adipose
tissue, synovium, skeletal muscle and deciduous teeth
(Barry and Murphy, 2004; Sonoyama et al., 2006).
MSCs possess the capacity to differentiate into cells of
connective tissue lineages, including bone (Noel et al.,
2002; Arinzeh, 2005; Hong et al., 2006), fat (Barry and
Murphy, 2004; Helder et al., 2007), cartilage (Noel et al.,
2002; Barry and Murphy, 2004; Caplan, 2007),
intervertebral disc (Trubiani et al., 2005, 2006;
Richardson et al., 2007), ligament (Trubiani et al., 2005,
2006; Sonoyama et al., 2006) and muscle (Ringe et al.,
2002; Barry and Murphy, 2004). A great deal has 
been learnt about the isolation, cultivation and
characterization of MSCs in recent years. A huge
amount of research effort is focussed on their
differentiation. MSCs have generated a great deal of
public, scientific and media interest because of their
potential use in regenerative medicine and tissue
engineering. This review will focus on autologous
chondrocyte transplantation (ACT) and selected tissue
engineering methodologies that employ mesenchymal
stem cells. The strengths and limitations of these
approaches for articular cartilage regeneration and
connective tissue repair will also be critically evaluated.
Osteoarthritis (OA)
Definition of OA
The word 'arthritis' literally means inflammation of
synovial joints, and refers to a group of more than 200
diseases that affect the joints. Osteoarthritis (OA) is the
most common type of arthritis. OA is the syndrome of
joint pain and dysfunction caused by joint degeneration
and affects more people than any other joint disease
(Buckwalter and Martin, 2006). OA is primarily
characterized by degeneration of articular cartilage
(Roach et al., 2007), intra-articular inflammation with
synovitis, and changes in peri-articular and subchondral
bone (Goldring and Goldring, 2007). OA, also known as
degenerative joint disease (DJD), may occur following
traumatic injury to the joint, subsequent to an infection
of the joint or simply as a result of ageing and the wear
and tear associated with the stresses of daily life.
Cartilage acts as a slippery cushion absorbing
mechanical loads, thereby facilitating low friction
movement of joints and allowing the ends of long bones
to glide over one another. The breakdown of articular
cartilage results in the loss of joint lubrication, causing
the bones to rub against each other and form bone spurs
or osteophytes. In some cases fragments of cartilage can
break off and float inside the joint space causing
obstruction, inflammation and further structural damage.
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The main symptoms of osteoarthritis are pain, stiffness
and swelling of the joints. The joint may have restricted
movement, and there may be tenderness or deformity.
The joint may also crack or creak a phenomenon that is
often described as crepitation (Stegenga et al., 1991;
Broussard, 2005). When the joint becomes severely
damaged, it may become misshapen, with numerous
osteophytes, leading to further instability. This puts
stress on the ligaments and tissues surrounding the
joints, and can lead to deformity.
Demographics of OA
OA is rare in people under 40 but becomes more
common with age - most people over 65 years of age
show some radiographic evidence of OA in at least one
or more joints. OA is the most frequent cause of physical
disability among older adults globally. More than 8
million people in the UK and over 20 million Americans
are estimated to have OA. It is anticipated that by the
year 2030, 20% of adults will have developed OA in
Western Europe and North America. OA is not only a
common problem among the elderly population, but also
it is becoming more widespread among younger people.
In the United States, RA and OA combined affect as
many as 46 million people. This amounted to a
healthcare cost of over $128 billion in 2003. This huge
financial burden emphasizes the acute need for new and
more effective treatments for articular cartilage defects.
Furthermore, there are currently no disease modifying
drugs or treatments for OA. Existing pharmaceuticals
include steroids and non-steroidal anti inflammatory
drugs which are unsatisfactory and only treat the
symptoms of OA by reducing pain and inflammation.
Therefore, OA represents a major opportunity for
research and development. Any new information gained
about new treatments developed for treating OA in
human patients will also have benefits to companion
animals such as horses and dogs which also suffer from
OA.
Established treatments for OA
Sensible treatments for OA include preventive
measures, i.e. removal or treatment of the inciting cause;
restoring joint stability; treating underlying metabolic or
endocrine diseases that are known to exacerbate OA.
Another major contributor to OA is obesity (Abramson
et al., 2006; Hunter, 2008). Therefore, weight control
and exercise regimes are recommended for overweight
patients with OA. A number of surgical methods and
procedures have been implemented to restore synovial
joint function. These range from minimally invasive
procedures such as arthroscopic abrasion (debridement)
and shaving of small cartilage defects, to more extended
surgical procedures such as microfracture of the
subchondoral bone and mosaicplasty. Surgery for OA,
which may involve joint replacement, is generally
unsatisfactory. Hip replacements are increasingly
common and give OA patients a new lease of life, with
improved mobility and significant pain relief. Hip
replacements are usually effective for at least 10 years -
after this, they may need to be replaced. Replacing the
knee is a much more complicated procedure, since the
knee joint is more complex than the hip joint.
Nevertheless, knee replacements can also bring OA
patients significant improvements in their quality-of-life.
Alternative and complementary therapies for OA are
controversial. Nutritional and nutraceutical therapies
have been proposed for OA. However, the use of
nutraceuticals is highly controversial and is debated
elsewhere (Hauselmann, 2001; Ringe et al., 2002; Barry
and Murphy, 2004; Goggs et al., 2005; Henrotin et al.,
2005; Trumble, 2005; McAlindon, 2006; Clark, 2007;
Frech and Clegg, 2007). Unfortunately, since joints have
a very poor capacity for healing and repair, cartilage
regeneration is generally minimal due to the limited
repair capacity of the cartilage tissue. The resulting
repair tissue often lacks the mechanical properties and
physical durability of the original articular cartilage.
This results in further degeneration of the cartilage and
continued decline in joint function.
In recent years, a range of methods have been
developed for the repair of articular cartilage lesions.
These include osteochondral transplantation, micro-
fracture and autologous chondrocyte transplantation
(ACT), with or without the assistance of a scaffold
matrix to deliver the cells. A feature of all of these
techniques is that their use is limited to the repair of
focal lesions and patients with OA are mostly excluded
from treatment. OA cartilage lesions are generally large
and unconfined and so do not provide an appropriate
environment for chondrocytes to be retained long
enough to synthesize an extracellular matrix. Therefore,
successful repair of OA cartilage lesions is only likely to
be achieved when 3-dimensional cartilage implants can
be generated that have enough extracellular matrix for
fixation within the joint.
Novel and innovative treatments for OA
ACT has been in clinical use for a decade but has
several major drawbacks. Challenges in treating
cartilage defects with ACT include paucity of the cell
source; damage caused to native tissues by cell harvest;
inability to restore the original cartilage structure (40%
of ACTs show evidence of chondrocytes hypertrophy);
lack of adhesion between new repair cartilage and the
original tissue. In general, most tissue engineered
scaffolds do not possess the appropriate biomechanical
properties (i.e. they are not sufficiently load-bearing).
The advent of mesenchymal stem cells (MSCs) and
tissue engineering has provided osteoarticular
pathologists, cell biologists and clinicians a new and
exciting medium for experimentation. It is often asked:
'Can tissue engineering and MSCs be used to treat OA?'
The optimistic answer is of course, 'yes'. However, the
realistic answer should be 'possibly' or 'hopefully'.
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Stem cells and tissue engineering for large bone defects
Another expanding area of research and clinical
development in connective tissue medicine and biology
is the healing of large bone defects. Large bone defects,
mainly those resulting from trauma, loss of large bone
areas after cancer surgery, or bone loss through
metabolic disorders connected with weakening of the
whole bone structure, require special treatments. Clinical
approaches include allografting and have established
themselves in routine clinical medicine. However, the
incidence of donor site morbidity, risk of infection from
allografts or sheer implant size have meant that
reconstructive medicine has reached bottle-neck
limitations. These requirements have guided the
development of new strategies, most of these evolving
around bio-compatible and bio-degradable scaffold
construction and seeding of scaffolds in vitro with
appropriate cells such as primary osteocytes or
mesenchymal stem cells (Krampera et al., 2006).
Potential of stem cells in treating tendinopathies
Tendon injuries are a major problem in clinical
medicine. Tendon injuries are often the consequence of
recurrent micro- or macro-traumata, continued
mechanical over straining or the side effect of other
medical therapies such as antibiotic treatment with
gyrase inhibitors such fluoroquinolones (Shakibaei et al.,
2000, 2001a; Shakibaei and Stahlmann, 2001, 2003;
Sendzik et al., 2005; Mehlhorn and Brown, 2007) .
Strategies of tendon repair evolve mainly around
allografting of tendons. In recent times, new approaches
using bio-compatible and bio-degradable scaffolds and
in vitro tissue engineering of tendon from tenocytes or
MSCs have been introduced and evaluated (Krampera et
al., 2006).
Challenges in connective tissue healing (bone, tendon,
cartilage)
There are a variety of problems associated with the
healing of connective tissues such as bone, tendon and
cartilage. Bone, compared to tendon and cartilage, heals
relatively quickly, through regenerating and remodelling
itself. The major advantage of bone tissue is its good
vascularisation, not only making it possible for new cells
to reach the site of a defect but also to remove and
dispose of apoptotic and necrotic tissue. However, large
bone defects resulting through trauma, tumors or
metabolic and degenerative diseases have a limited
capacity for self repair. This highlights the acute need for
readily available, implantable bone grafts (Beris et al.,
2005; Kajiwara et al., 2005).
Autogenous and/or allogenic osteochondral grafts
have been used for several decades to fill osteochondral
defects. A wealth of clinical experience has thus far been
gathered. Patients with large defects such as large
osteochondoral defects after tumor resection,
osteonecrosis, extensive trauma or broad focal OA have
especially benefited from these grafts (Meyers et al.,
1983; Czitrom et al., 1986; Marco et al., 1993).
However, autogenous grafts are frequently connected
with donor site morbidity (Hangody and Fules, 2003).
Furthermore, allografts always increase the risk of
infections and they must be immunocompatible with the
patient to avoid implant rejection and peripheral bone
necrosis. These problems have led to new research to
provide bone substitutes produced in vitro through tissue
engineering. Today, bone tissue engineering is a dynamic
and rapidly expanding field. The main focus is on
scaffolds which provide an artificial extracellular matrix
for the colonization of appropriate cells such as primary
osteoblasts and various combinations of growth factors.
Tendon and cartilage exhibit bradytroph properties in
vivo and possess very limited regeneration capacities
(Schulze-Tanzil et al., 2004a). Tendons represent an
essential part of the musculoskeletal system linking the
dynamic (muscles) to the static (bone) components. To
be able to meet the demand of the mechanical
environment, tendons must have a highly specialized
extracellular matrix (ECM), consisting of parallel
aligned fibres capable of withstanding tensile loads.
Thus, tendon consists of large quantities of ECM and
few cells (tenocytes) which produce this highly
specialised matrix. More than 95% of tendon ECM is
made up of collagen type I, but other collagens (type III
and V) as well as proteoglycans, elastin, fibronectin are
also present (Kannus, 2000; Canty and Kadler, 2002;
Schulze-Tanzil et al., 2004a). Its marginal
vascularisation and the low mitotic activity of the
tenocytes are major factors and contributors to the poor
repair and regeneration potential of tendons (Ahmed et
al., 1998).
Cartilage is another connective tissue that owes its
special characteristics to the dense ECM produced by
chondrocytes. About 40 to 50% of cartilage ECM
consists of collagens (of these, approximately 90% is
collagen type II) and about 20 to 25% of different
proteoglycans (aggrecan, decorin, biglycan and
fibromodulin). A particular feature of its cells, the
chondrocytes (which make up less than 5% of the
tissue's total 3-dimensional volume) is that they do not
have any direct cell-to-cell contact with each other.
Thus, each cell may be regarded as a functional unit
responsible for maintaining the ECM in its immediate
surrounding through balanced and tightly regulated
anabolic and catabolic activities. Cartilage is avascular,
aneural and alymphatic (Bora and Miller, 1987). This
unique composition further explains the limited repair
capacity of articular cartilage and why most repair
tissues fail due to the dominance of a fibroblast-like cell
type which produces an ECM without the necessary
biomechanical properties of hyaline cartilage (Vachon et
al., 1986; Cancedda et al., 2003).
During embryogenesis, cartilage is formed from the
condensation of mesenchymal stem cells (MSCs).
Mesenchymal cell aggregates, termed blastema in vivo,
precede cartilage differentiation in vivo and also in high-
density cell cultures (Aulthouse and Solursh, 1987;
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Solursh, 1989). This process is characterized by the
production of cartilage matrix specific proteoglycans and
a switch from collagen type I to collagen type II
synthesis (Cancedda et al., 1995). In articular cartilage
chondrocytes stay at a mature state. However, in
adolescents during endochondral bone development,
chondrocytes become hypertrophic, produce alkaline
phosphatase and collagen X and are eventually
reabsorbed while new bone is formed in the growth
plate.
Clinical methods for carti lage repair: Autologous
Cartilage Transplantation (ACT)
Throughout life our bodies are constantly exposed to
external and internal stresses. In order to survive and
maintain optimal health, it is essential for the body to be
able to repair and regenerate damaged tissues. This is
normally achieved by replacement of dead, dying and
damaged cells with progenitor cells that have the
capacity to differentiate into the specialised cell type
being replaced. For example, in tissues such as the
intestine or the skin, regeneration is accomplished via
proliferation and differentiation of unspecialised
multipotent resident cells, the stem cells (Tallheden et
al., 2006).
As discussed earlier, articular cartilage is a poorly
vascularised tissue and when it is damaged
chondroprogenitor cell access to the damaged site will
be very limited. Consequently, a new method termed
Autologous Cartilage Transplantation (ACT) was
introduced by a Swedish group following the general
principles of tissue repair (Brittberg et al., 1994). ACT
was designed as a novel clinical treatment for articular
cartilage repair to solve the problem of progressive
degeneration in OA joints. The idea was to fill up the
cartilage defect with autologous chondrocytes (i.e.
derived from the same patient), combining surgical
treatment with in vitro methods. The chondrocytes
would be placed into the defect and through this
transplantation cell condensation would be triggered,
mimicking the condensation phase in early embryonic
development. This condensation phase would give the
chondrocytes a new stimulus for matrix production and
hence lead to restitution of hyaline cartilage tissue in the
cartilage defect. Today, many modifications of the
technique exist and are used in the clinic. The basic
techniques for the clinical application of chondrocyte
implantation has been re-evaluated by Brittberg who has
also provided an update on the clinical results (Brittberg,
2008).
The ACT method is briefly summarized in this
section. A biopsy (ca. 150-300mg cartilage tissue) is
surgically taken from a non weight bearing area of the
affected joint, for example from the supromedial edge of
the femoral condyle in the knee, and transferred to a
special sterile, nutrient solution for transport. In the cell
culture laboratory, chondrocytes are then isolated from
the cartilage tissue through enzymatic digestion with
collagenase and pronase. The chondrocytes are then
seeded in vitro in monolayer culture and expanded. The
goal of the in vitro expansion is to obtain a sufficient
number of cells for re-implantation to be able to fill up
the cartilage defect. In a second surgical procedure, the
in vitro expanded chondrocytes are then injected into the
defect. To secure the chondrocytes remaining at the
implanted side and to prevent the mass from floating
away, a periosteal flap is further sewed over the defect
(Brittberg et al., 1994). It is well documented that the
periosteal flap alone can have chondrogenic capacities,
and induce cartilage regeneration. However the precise
role of the periosteum still remains to be elucidated.
Results of long-term studies
In the first animal experiments performed on rabbits,
the ACT technique was performed on chondral defects
that had not penetrated the subchondral bone. These
results were very encouraging; the rabbits showed new
cartilage formation in 82% of the defect area (Grande et
al., 1989). In further studies, chondral defects of the
patella in rabbits were either treated with chondrocytes
or left empty with only the periosteal flap covering the
defect (Brittberg et al., 1996), or scaffolds were used
with chondrocytes seeded into an agarose gel and then
transplanted (Rahfoth et al., 1998). In both cases, the one
year outcome showed significantly higher hyaline
cartilage production in treatments with added
chondrocytes compared to control treatments without
cells (between 47 to 87%). To evaluate whether the
implanted chondrocytes stayed at the implantation site or
whether tissue repair was performed by other cells,
chondrocytes were membrane labelled with a fluorescent
dye to track them after implantation in vivo. A six week
outcome in a goat model showed that cells persisted in
the defect site (Dell'Accio et al., 2003). In contrast to the
rabbit studies, a canine model showed no significant
difference between the ACT treated areas and the
controls (Breinan et al., 1997). However, in a canine
study, a scaffold seeded with chondrocytes was used
which showed significantly higher values of defect
regeneration (42% of defect area filled with hyaline
cartilage) (Lee et al., 2003).
ACT has been in clinical use in human patients since
1987 and has been performed on over 12,000 patients
worldwide (Peterson et al., 2002). ACT has significantly
reduced pain in patients - even the production of durable
cartilage-like tissue has been observed (Peterson et al.,
2002). In human patients, results after three to nine years
are very encouraging, although repair of the defect is not
uniform in all areas of the joint (Brittberg et al., 1994;
Peterson et al., 2000). Although clinical results are
encouraging and overall the patients are satisfied, it must
be borne in mind that there is still a lack of comparative,
blinded, long term group studies in human subjects.
Problems with ACT
Despite the encouraging clinical results there are still
limitations to the use of ACT. These are mainly related
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to: a) the complexity of the surgical procedure, b) the
biological response of the periosteal flap, and c) the de-
differentiation and consequent capacity loss associated
with in vitro expansion of isolated chondrocytes
(Schulze-Tanzil et al., 2002, 2004b; Brittberg et al.,
2003; Dell'Accio et al., 2003). Most clinical
complications associated with ACT in fact are connected
to the periosteal flap. These include periosteal flap
detachment, delamination and late periosteal
hypertrophy (Brittberg, 1999).
One of the main hurdles to successful cartilage
repair is chondrocyte dedifferentiation during the
monolayer expansion phase. Within articular cartilage,
chondrocytes have a distinct round to oval morphology;
cells remain embedded close to their surrounding ECM.
The tight interaction between chondrocytes and the
ECM represents a major factor in the maintenance of
chondrocyte function, vitality and its unique biosynthetic
programme (Shakibaei et al., 1993, 1997; Shakibaei and
De Souza, 1997; Shakibaei and Merker, 1999). Damaged
ECM or its complete absence will result in a major shift
in chondrocyte gene expression. Instead of producing
cartilage specific proteoglycans and collagen type II,
chondrocytes switch to making non-specific
proteoglycans and collagen type I (von der Mark et al.,
1977; von der Mark, 1980; Marlovits et al., 2004). These
matrix components lack the biomechanical properties
and the resilience of articular cartilage. The monolayer
culture conditions in vitro, where chondrocytes are
forced to give up their round shape in order to adhere to
the plastic in order to survive, are a key component of
chondrocyte de-differentiation. This becomes
phenotypically evident after the cells adhere to tissue
culture plastic and continue de-differentiating with
prolonged culture. These de-differentiated cells are no
longer capable of re-differentiation when re-implanted in
the cartilage defect. Re-differentiation in 3-dimensional
surroundings of the cultured chondrocytes can be
achieved up to the fourth passage in monolayer
(Schulze-Tanzil et al., 2002). Furthermore, growth
factors are known to be involved in the re-differentiation
of chondrocytes. It has been shown that the insulin like
growth factor I (IGF-I) as well as transforming growth
factor beta (TGF-ß) influence and modulate the collagen
network in cartilage and can prolong the re-
differentiation capacity of monolayer expanded
chondrocytes (Hunziker, 2001; Barbero et al., 2003;
Jenniskens et al., 2006). Indeed, it has been shown that
treatment of monolayer cultured chondrocytes with IGF-
I will prolong their re-differentiation potential. After a
protracted monolayer expansion phase, IGF-I treated
chondrocytes are still able to produce specific cartilage
matrix components in 3-dimensional conditions in
comparison to chondrocytes not exposed to IGF-I
(Shakibaei et al., 2006).
New perspectives on classical ACT
New approaches in vivo and in vitro to modify the
classical ACT method have been examined. These so
called second and third generation ACTs include various
biomaterials to replace the peristoeal flap and a large
variety of scaffold materials as chondrocyte carriers to
the defect site (Marlovits et al., 2006). Furthermore, in
vitro studies have been implemented to study the
molecular mechanisms and signal transduction pathways
involved in chondrogenesis to precisely influence de-
differentiation of chondrocytes.
Second generation ACT uses a bi-layer collagen
type I/type III membrane (such as Chondro-Gide™) to
be sutured over the defect instead of the periosteal flap.
The cell suspension is then injected underneath. Using a
collagen membrane brings the added advantage of
reducing the time needed for surgical procedures, since
the preparation of the periosteal flap is no longer
necessary. Furthermore, using the collagen membrane
reduces the complications at the implant site connected
with the periosteal flap usage (i.e. periosteal
hypertrophy).
The so-called third generation ACT goes one step
further by attempting tissue engineering cartilage in vitro
through culturing chondrocytes on scaffolds. In general,
tissue engineering can be defined as the art of
reconstructing mammalian tissue, both structurally and
functionally (Hollander et al., 2006). This reconstruction
process can be performed entirely in vitro, with whole
new mature tissue being transplanted or partially in vitro
and the not fully matured tissue construct matured
further after transplantation in vivo. Naturally success in
tissue engineering of any connective tissue would make
tissue transplantation and grafting redundant.
In the case of cartilage tissue engineering, after
expansion in monolayer culture, chondrocytes are
seeded onto a 3-dimensional scaffold before
transplantation into the defect. The properties of these
scaffolds follow basic principles; they must be
biocompatible, structurally and mechanically stable and
must support the loading of an appropriate cell source to
allow successful infiltration and attachment to the host
tissue (Tuli et al., 2003). The composition of these
scaffold materials varies greatly and a large variety have
been tested in vitro and in vivo (Hunziker, 2002). There
are a wide variety of materials used such as polylactide-
co-glycolide (PLG) based (Mercier et al., 2005),
hyaluronan-based (Solchaga et al., 2005b) or
atelocollagen based (Ochi et al., 2002) scaffolds. Studies
on animals (Wakitani et al., 1998; Solchaga et al.,
2005b) and human patients (Ochi et al., 2002) have been
performed. Results were positive, but some human
patients showed signs of hypertrophy and partial
ossification of the implants (Ochi et al., 2002).
Cartilage tissue engineering has been attempted with
scaffold free techniques (Marlovits et al., 2003; Kelm
and Fussenegger, 2004) and applied in animal models
(Mainil-Varlet et al., 2001). For example, autologous
cartilage implants fixed with titan-suture-anchors have
been tested in horses where histological analysis of one
euthanized horse showed repair of a defect with a tissue
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similar to native cartilage after a period of 24 months.
Nevertheless, other problems with ACT still remain,
such as poor integration of repair tissue into the
surrounding cartilage. This limitation has been
recognized by several authors (Ahsan et al., 1999;
Hunziker, 2001, 2002). Histological staining reveals a
clear margin between the implant and the native tissue
and often there is apoptosis and necrosis at the interface
between the two. Although various measures, such as
collagen-cross linkers and biological glues have been
used to enhance tissue integration after implantation
(Grande and Pitman, 1988; Jurgensen et al., 1997; Ahsan
et al., 1999) they have been relatively unsuccessful.
Furthermore, the required size of the tissue engineered
constructs is often overlooked ((Hunziker, 2002). This is
particularly important when comparing the size of
experimental animals (such as rabbit and goat) and their
artificially induced defects with the size of human
chondral lesions. Whether large enough tissue
engineering constructs are able to be created for human
patients is an important question that highlights many
problems. These problems focus on the properties of
large implants to withstand mechanical loading and
stress, survival of the cells in the tissue engineered
implant and thus survival of the implant tissue.
The above mentioned problems are connected
mainly with physical and clinical procedures. However,
new strategies involving ACT improvement have to
center around enhancing and prolonging the
chondrogenic potential of the chondrocytes during their
in vitro expansion phase. This is of vital importance
since the core component of hyaline cartilage
regeneration is dependent on the potential of the
chondrocytes to re-differentiate and produce adequate
hyaline cartilage matrix. As stated above, the
chondrocytes from the biopsy have to be expanded in
monolayer to yield enough chondrocytes to fill up the
cartilage defect. However, this expansion phase leads to
a loss of their chondrogenic phenotype and re-
differentiation potential and thus results in the
chondrocytes being incapable of cartilage production
after in vivo implantation (Schulze-Tanzil et al., 2002,
2004b). To achieve success in tissue engineering it is
important to gain a better understanding of the
biochemical and molecular signaling pathways involved
in chondrogenesis. This knowledge would enable
scientists to specifically stimulate these pathways and
systematically induce the cells to re-differentiate into
cartilage matrix producing chondrocytes.
Several in vitro studies have been performed to
better understand chondrocyte physiology and the
molecular signaling pathways involved in cartilage
differentiation. A major signaling pathway involved in
activation of the chondrogenic differentiation of
chondrocytes is the MAPkinase pathway (Shakibaei et
al., 2001b; Schulze-Tanzil et al., 2004b). This pathway
stimulates the major chondrogenic transcription factor
Sox9. The MAPkinase pathway can be stimulated
through a variety of factors. Growth factors, such a 
IGF-I and TGF-ß, have been proven to interact with their
cell surface receptors and stimulate the adaptor protein
Shc (Shakibaei et al., 2006). Stimulation of Shc leads to
subsequent stimulation of ERK1/2 and further kinases of
the MAPK pathway. In vitro stimulation of monolayer
chondrocytes with IGF-I prolongs their potential to re-
differentiate and produce cartilage specific matrix
components such as collagen type II and cartilage
specific proteoglycans (Shakibaei et al., 2006). This
approach could become a valuable tool for future applied
ACT strategies, since it provides adequate numbers of
chondrocytes that are still able to re-differentiate in vivo
and thus produce adequate hyaline cartilage matrix. This
would provide a new, sound basis for chondrocyte-
based cartilage tissue repair.
Other methods for cartilage repair
In the following sections we define and discuss
microfracture and mosaicplasty before reviewing and
justifying the use of mesenchymal stem cells for
cartilage repair.
Microfracture
There are a variety of other techniques used to
attempt clinical cartilage regeneration (Hunziker, 2002).
Two of these; the microfracture method and the
mosaicplasty method, will be briefly discussed here. The
microfracture technique is an intervention which does
not use biological agents, such as chondrocyte implants.
During the surgical procedure, the surgeon drills small
holes into the surface of the cartilage over the defect
area. The holes are 3-4mm apart and 4mm deep. The
rationale behind this is that the drilling of the holes
stimulates a spontaneous repair reaction. It is notable
that the microfracture technique has been mainly applied
in young individuals and athletes, with whom it yields
relatively good results in regard to regaining of joint
function and pain relief (ca. 75%) (Sledge, 2001).
However, no studies on OA patients exist. Thus, it
remains questionable whether microfracture can achieve
such good results in OA patients where the regenerative
potential of cartilage is already diminished.
Mosaicplasty
Mosaicplasty or Autogenous OsteoChondral
Grafting (AOCG) is a breakthrough technique which is
the result of more than a decade of animal and clinical
research and refinements in surgical technique and
instrumentation. It has been in clinical use since 1992
and has been shown to be an efficacious, reproducible,
and cost-effective means of restoring chondral defects.
This procedure is indicated for the treatment of focal,
full thickness, cartilage lesions of up to 9 cm in the knee
and ankle. Mosaicplasty basically involves the
implantation of whole osteochondral tissue into the
cartilage defect. The idea of implanting autologous or
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allogenic osteochondral grafts to repair cartilage defects
dates back to the beginning of the last century. This
technique has been clinically tried, tested and refined.
Thus far there is a considerable amount of clinical data
available on this technique (Hangody et al., 2001a,b). In
mosaicplasty round 'plugs' of cartilage and underlying
bone are excised from healthy non-weight-bearing areas
and moved to damaged areas. The plugs are each a few
millimeters in diameter, and when multiple plugs are
moved into a damaged area the result is a mosaic
appearance-the multiple small plugs of cartilage look
like mosaic tiles. The first step is to prepare the area of
damaged cartilage. A coring tool is used to make a
perfectly round hole in the bone in the area of damage.
This hole is sized to fit the plug. The second step is to
'harvest' the plug of normal cartilage. The plug is taken
with the underlying bone to fit into the hole that was
prepared in the area of damage. The plug is just slightly
larger than the hole so it will fit snugly into position. The
final step is to implant the harvested plugs into the hole
that was created in the damaged area. Over time, the
hope is that the implanted bone and cartilage will
incorporate and integrate into its new environment.
The results of mosaicplasty appear promising with
60 to 90% of the patients reporting pain relief and
restored joint function. However, no blinded clinical
trials been done and therefore results must be regarded
with caution. Animal studies have been performed on
both small experimental animals such as rabbits and on
large animals such as the horse. The successful treatment
of an equine subchondral cystic lesion with mosaicplasty
has been reported (Bodo et al., 2000). Although a study
with horses reported resistant and consistent integration
of the osteogenic part of the graft for a long period of
time, the cartilage part of the graft was resorbed after 6
months. Studies with the sheep have given similar
results, showing not only resorption of the chondral part
of the graft, but also degeneration of the adjoining
cartilage tissue (Wohl et al., 1998; Bodo et al., 2000).
The poor integration of the implants into the defects is
connected to the translocation of a graft from a non
weight bearing area to a weight bearing area, leading to
physiological stress through mechanical overloading of
the cartilage. Furthermore, the tissue can be damaged
when the implants are hammered into the defect by the
transplanting surgeons (Quinn et al., 1998a,b).
Therefore, the results of the mosaicplasty method appear
ambiguous and must be regarded with caution.
Stem cells for connective tissue regenerating medicine
and cartilage repair
There are several limiting factors when using
autologous chondrocytes. Each biopsy is an additional
trauma to cartilage that is already damaged and injured
in the joint. Furthermore, suitable donor sites for hyaline
cartilage are rare in damaged joints, and as yet, other
cartilage has not been fully assessed for its ability to
repair articular cartilage (hyaline nasal or rib cartilage)
(Naumann et al., 2002). In addition, the number of cells
obtained via biopsy is relatively small and therefore the
cells have to be expanded for several passages.
Chondrocytes grown in monolayer de-differentiate with
passaging and subsequently lose their chondrogenic
phenotype and their re-differentiation potential. This loss
of cartilage specific matrix components is indicated
mainly through a switch in the cells from producing
collagen type II to collagen type I (von der Mark et al.,
1977; Darling and Athanasiou, 2005). It has been shown
that re-differentiation is possible with the help of
specific growth factors such as TGF-ß (Denker et al.,
1999; Jakob et al., 2001; Barbero et al., 2003) as well as
without growth factors (Anderer and Libera, 2002).
However to avoid further distress for the traumatized
joint and initially obtain high numbers of cells, an
alternative source of cells with chondroprogenitor
potential would be useful. One such possibility for the
construction of neo-cartilaginous tissue is the use of
mesenchymal stem cells (Caplan and Goldberg, 1999).
What are stem cells?
Tissue engineering has rapidly evolved as a new and
exciting field of basic research, investigating how to
repair and regenerate tissues by mimicking in vitro key
features of developmental pathways in tissue formation
using a combination of growth factors and biomaterials
(Caplan and Goldberg, 1999). In the last decade a new
understanding of embryonic development has led to the
therapeutic approach of repairing skeletal tissue through
tissue engineering and the reconstruction of pieces of
cartilage and bone for subsequent implantation has
opened up whole new regenerative medical strategies
(Caplan, 1991, 2000, 2007; Cancedda et al., 2003; Short
et al., 2003).
Stem cells have the remarkable potential to develop
into many different cell types in the body. The various
different applications of cultured stem cells have been
summarized in Figure 1. In addition to serving as a sort
of repair system for the body, they can theoretically
divide without limit to replenish other cells as long as
the person or animal is still alive. Stem cells have two
fundamental characteristics that distinguish them from
other types of cells. First, they are unspecialized cells
that renew themselves for long periods through cell
division. The second is that under certain conditions they
can be induced to become specialized cells with unique
biological functions (Fig. 1).
An un-differentiated progenitor cell, ideally present
everywhere in the body and yet capable of
differentiating into various mesenchymal, epidermal and
endodermal specialized tissue/organ cells is the ideal
stock material from which an in vitro tissue engineered
tissue replacement could be made (Fig. 2). Stem cells are
a promising cell source that fulfill these requirements for
tissue engineering. In general, a stem cell is described as
an unspecialized progenitor cell that resides in niches in
various organs and tissues from where it can be recruited
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to replenish specific tissue cells when they die (Fuchs et
al., 2004; Caplan and Dennis, 2006). Stem cells can be
found in the embryo, fetus and the adult individual. Stem
cells are capable of differentiation, therefore using stem
cells from the adult individual has two advantages:
firstly, the ethical considerations which are associated
with attaining stem cells from the embryo are redundant
and secondly, autologous cells could be recovered for
tissue engineering implant production thereby
circumventing any possible immunomodulatory
responses after allogenic graft implantation. However, in
contrast to embryonic stem cells which are pluripotent,
adult or fetal stem cells are multipotent and hence have
reduced differentiation capacities (Fig. 2). In adult
individuals, stem cells have been identified in various
organs and tissues. The earliest identified stem cells
belong to the hematopoietic lineage and are all derived
from hemocytoblasts in the bone marrow. Hematopoietic
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Fig. 1. Applications of cultured pluripotent stem
cells. The various applications of stem cells are
summarized in this schematic.
Fig 2. The hierarchy of stem cells. The potency
of stem cells specifies the differentiation
potential of stem cells. Totipotent stem cells are
produced from the fusion of an egg and sperm
cell. Cells produced by the first few divisions of
the fertilized egg are also totipotent. These
cells can differentiate into embryonic and extra-
embryonic cell types. Pluripotent stem cells are
the descendants of totipotent cells and can
differentiate into cells derived from any of the
three germ layers. Multipotent stem cells can
produce only cells of a closely related family of
cells (e.g. hematopoietic stem cells differentiate
into red blood cells, white blood cells, platelets,
etc. and other stem cells which include
mesenchymal stem cells). Unipotent cells only
have the capacity to produce one cell type, but
have the property of self-renewal which
distinguishes them from non-stem cells (e.g.
muscle stem cells).
stem cells give rise to all the blood cell types including
myeloid and lymphoid lineages (Fig. 3). The definition
of hematopoietic stem cells has undergone considerable
revision in the last two decades. The hematopoietic
tissue contains cells with long term and short term
regeneration capacities and committed multipotent,
oligopotent and unipotent progenitors.
Today, adult stem cells have been isolated from a
large variety of organs including peripheral blood, bone
marrow, muscle, fat, pancreas, skin, the central nervous
system and many other tissues (Till and McCulloch,
1980; Caplan, 1991; Williams et al., 1999; Zuk et al.,
2001; Alexanian and Sieber-Blum, 2003; Bottai et al.,
2003; Cancedda et al., 2003). Over the last two decades
it was discovered that the bone marrow hosts not only
hematopoietic stem cells but also contains a pluripotent
mesenchymal fibroblastic progenitor cell type that can
differentiate towards bone, muscle, fat, cartilage and
other connective tissues in vitro (Caplan, 1991; Fortier et
al., 1998; Conget and Minguell, 1999; Pittenger et al.,
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Fig. 3. Differentiation of hematopoietic stem
cells. Hematopoietic stem cells are multipotent
stem cells which have the capacity to give rise
to all the blood cell types including myeloid
(monocytes and macrophages, neutrophils,
basophils, eosinophils, erythrocytes, mega-
karyocytes/platelets, dendritic cells) and
lymphoid lineages (T-cells, B-cells, NK-cells).
They may also have the capacity to give rise to
neuronal cells through a poorly understood
process known as stem cell plasticity.
Fig. 4. Applications of cultured mesenchymal
stem cells. Mesenchymal stem cells have the
capacity to differentiate into connective tissue
and musculoskeletal cells for t issue
engineering, autologous implantation/
transplantation and regenerative medicine.
This process involves commitment, lineage
progression, differentiation and maturation.
Mesenchymal stem cells have recently been
shown to differentiate into pancreatic islet cells.
Mesenchymal stem cells may also have the
capacity to give rise to neuronal cells through a
process known as transdifferentiation.
1999; Majumdar et al., 2000; Short et al., 2003; Kramer
et al., 2004; Otto and Rao, 2004) (Fig. 4).
MSCs represent 2-3% of the total mononuclear cells
in bone marrow and can be isolated and expanded for
several passages without loosing their ability to
differentiate (Pittenger et al., 1999). In monolayer
culture they show a typical colony forming fibroblast-
like morphology which they maintain throughout many
passages and they express several adhesion molecules
found also in mesenchymal, endothelial and epithelial
cells (Conget and Minguell, 1999). Extraction of bone
marrow is easily obtained by bone marrow aspirates
(Caplan et al., 1997). The bone marrow is immediately
diluted in 3% citric acid or heparin and, after transport to
a cell culture laboratory, the stem cells are isolated
mainly through density gradient centrifugation, magnetic
bead sorting or FACS analysis. The International Society
for Cellular Therapy has listed the main factors required
for a cell to be regarded as a mesenchymal stem cell in a
position statement (Dominici et al., 2006). Mesenchymal
stem cells are characterized through their adhesion
potential in monolayer culture and through their
differentiation potential into chondrocytes, osteocytes
and adipocytes in vitro (Fig. 5). Furthermore, the
International Society for Cellular Therapy has listed
several markers that cells should exhibit or lack in order
to be classified as MSCs. Markers that MSCs should
exhibit include CD105+, CD73+ and CD90+, whereas
MSCs should lack CD45-, CD34- and several other
hematopoietic stem cell markers (Dominici et al., 2006).
Other sources for the isolation of mesenchymal stem
cells include umbilical cord blood (Bieback et al., 2004;
Kogler et al., 2004), adipose tissue (Zuk et al., 2002;
Kern et al., 2006), synovial cells (De Bari et al., 2001;
Sakaguchi et al., 2005; Koga et al., 2007) and peripheral
blood (Huss et al., 2000; Zvaifler et al., 2000; Ukai et
al., 2007). Adipose tissue in animals seems to be a good
and plentiful source of MSCs (Qu et al., 2007;
Yamamoto et al., 2007). Umbilical cord blood has
proven to be a good source of MSCs. Human cord blood
non-haematopoietic stem cells have been differentiated
into multiple cell types such as endothelial cells,
neurons, smooth muscle cells, adipocytes, chondroblasts
and osteoblasts (Aoki et al., 2004; Bieback et al., 2004;
Kogler et al., 2004; Watt and Contreras, 2005; Qu et al.,
2007; Yamamoto et al., 2007). There has been some
discussion and debate about the routine collection and
deep freezing of umbilical cord blood from babies in
case the need arises in later life. Umbilical cord blood
derived MSCs are already commercially available for
horses and humans. The equine sporting industry is
hoping for regeneration of cartilage and tendon injuries
with umbilical cord blood derived MSCs (Koch et al.,
2007).
Adipose tissue is another alternative stem cell source
that can be obtained by less invasive methods and in
larger quantities than bone marrow. It has been
demonstrated that adipose tissue contains stem cells
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in the cells. Oil Red O staining
for lipids revealed that these
vacuoles indeed contain
neutral lipids (arrows). After
21 days the high density
cultures treated with
chondrogenic induction
medium (i.e. TGFß-1 and
dexamethasone) were
intensely stained with Alcian
blue revealing a high content
of carti lage specif ic
proteoglycans. B, x 10; C, D, x
40
Figure 5: Light microscopic
demonstration of osteoid, adipose and
carti lage tissue formation with von
Kossa, Oil Red O and Alcian blue
staining. Cells changed with the
osteogenic induction medium from a
fibroblastic appearance to a more
cuboidal appearance, were surrounded
with an abundant matrix and formed
mineralised nodules. After three weeks
in culture, the stimulated cells were
stained positive with von Kossa stain for
mineral deposition in their newly formed
extracellular matrix (arrows). In the
monolayer cultures treated with
adipogenic induction media an
abundance of vacuoles were observed
similar to bone marrow-MSCs, which are termed
processed lipoaspirate (PLA) cells (Zuk et al., 2002).
These cells can be isolated from cosmetic liposuctions in
large numbers and grown easily under standard tissue
culture conditions. The multilineage differentiation
capacity of PLA cells has been confirmed. It has also
been observed that human adipose tissue yields higher
amounts of MSCs then bone marrow or umbilical cord
blood (Kern et al., 2006). However, in humans it seems
that bone marrow obtained MSCs have superior
chondroprogenitor capacities compared to adipose tissue
derived MSCs (Im et al., 2005).
Chondrogenic stem cell differentiation
Current attempts at chondrogenic differentiation of
MSCs are based on the knowledge of chondrogenic
development, cartilage homeostasis and function. The
use of mesenchymal stem cells for articular cartilage
repair is based on the awareness that in vivo, during
embryogenesis, limb formation occurs through the
condensation of mesenchymal cells which then
differentiate to the chondral pre-skeleton and form the
cartilage covering the articulating surface of the joint.
Chondrogenesis in vitro requires two major
components: firstly a 3-dimensional environment (Fig.
6) and secondly the addition of various combinations of
growth factors to stimulate chondrogenic signaling
pathways in the MSCs. The micromass pellet culture as
described by Pittenger and co-workers is the most
frequently used system (Pittenger et al., 1999). Here,
250,000 to 500,000 MSCs are centrifuged in a conical
tube and then incubated for various time periods ranging
from 14 to 21 days at 37°C in a humidified atmosphere.
After one day in culture, the cells aggregate and form a
round cell pellet. Other 3-dimensional culture methods
for cartilage formation include high density bridge
cultures (Fig. 6) and alginate beads cultures (Shakibaei
and De Souza, 1997; Lange et al., 2005).
Since the discovery that MSCs can be directed
towards the chondrogenic lineage, many attempts have
been made towards cartilage tissue engineering (Caplan
and Goldberg, 1999; Magne et al., 2005). It is well
known that MSCs can be stimulated towards the
chondrogenic lineage with a variety and various
combinations of soluble factors (Fig. 7). These include
TGF-ß1, IGF-1, dexamethasone, the family of bone
morphogenic proteins (BMPs) and fibroblast growth
factor (FGF) (Grigoriadis et al., 1988; Denker et al.,
1999; Pittenger et al., 1999; Nixon et al., 2000; Carlberg
et al., 2001; Tsutsumi et al., 2001; Nakayama et al.,
2003).
TGF-ß1 is the most commonly used growth factor
for in vitro chondrogenic differentiation of MSCs
(Caplan, 1991; Johnstone et al., 1998; Pittenger et al.,
1999). TGF-ß1s mechanism of action has not yet been
fully elucidated. The TGF-ß1 and Wnt signaling
pathways enhance proliferation of MSCs and
simultaneously inhibit their differentiation towards
osteoblasts and adipocytes (Zhou et al., 2004; Jian et al.,
2006). Longobardi and co-workers showed that a part of
its mechanism is mediated by ERK1/2 MAPKinase
signaling pathway (Longobardi et al., 2006). Thereby
they could show that ERK1/2 mediates mitogenic
properties of TGF-ß, however collagen type II
production is independent from this. The observation of
Jaiswal and colleagues that activation of ERK1/2 plays
an important role in osteogenesis of MSC and that the
inhibition of the MAPKinase pathway leads to
adipogenesis agrees with these findings (Jaiswal et al.,
2000). Longobardi et al. also showed that IGF-1
independently from TGF-ß can regulate chondrogenesis
in MSCs and that the signal transduction pathway of
IGF-1 only partly runs via the MAPKinase pathway
(Longobardi et al., 2006). They postulate a synergism
between TGF-ß and IGF-1, which positively stimulates
chondrogenesis in the MSCs. Expression of the
chonodrogenic specific transcription factor Sox9, the
quantities of collagen type II and the cartilage specific
proteoglycans (CSPG) in MSCs stimulated both with
TGF-ß and IGF-1 was comparable to that of mature
adult chondrocytes (Longobardi et al., 2006). Derfoul
and co-investigators studied the mechanism of action of
dexamethasone, a synthetic glucocorticoid, and showed
that in MSCs chondrogenesis was directly stimulated via
the glucocorticoid receptor. Additionally it enhances
TGF-ß mediated collagen type II and CSPG, i.e.
aggrecan, production (Derfoul et al., 2006). Furthermore
it has been described that MSCs from various animals
such as horses, rabbits and cattle could be differentiated
towards chondrocytes with dexamethasone as the main
medium supplement (Grigoriadis et al., 1988; Johnstone
et al., 1998; Bosnakovski et al., 2005). Proteins
belonging to the BMP family of proteins can also
stimulate chondrogenesis in MSCs in vitro (Luyten et
al., 1992; Sailor et al., 1996; Chubinskaya and Kuettner,
2003; Schmitt et al., 2003; Indrawattana et al., 2004;
Knippenberg et al., 2006). Stimulation of MSCs with
BMP-7 has been shown to lead to chondrogenesis
(Knippenberg et al., 2006). Therefore, BMP-7 seems to
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Fig. 6. Schematic of the three dimensional system for high density
cultures. A nitrocellulose filter is placed on a steel-net-bridge and cells
are cultured on the filter. Cell culture medium reaches the filter-medium
interface, nurturing cells through diffusion, thus mimicking an
environment similar to that found in vivo.
suppress osteogenic differentiation pathways in the
MSCs. Contrary to this, sole stimulation with BMP-2
seems to stimulate osteogenesis (Knippenberg et al.,
2006), while a combination of BMP-2 and TGFß-3 leads
to chondrogenesis (Schmitt et al., 2003).
Chondrogenesis, through combination treatment of
BMP-6 and TGFß-3, has also been described
(Indrawattana et al., 2004). It is well known that BMP-2
cooperates with the Wnt signal transduction pathway.
BMP-2 can upregulate Wnt3a, leading to accumulation
of ß-Catenin and the subsequent induction of Sox9 and
chondrogenesis (Fischer et al., 2002a,b). Upregulation of
ß-Catenin is essential to commit a cell to the
chondrogenic lineage (Day et al., 2005; Hill et al., 2005).
However, in mature adult chondrocytes, ß-Catenin can
also stimulate chondrogenic hypertrophy and
ossification (Kitagaki et al., 2003; Tamamura et al.,
2005). This is a logical step since although articular
cartilage chondrocytes normally stay at a mature state, in
growing adolescents the chondrocytes become
hypertrophic, produce alkaline phosphatase and collagen
type X and are then eventually reabsorbed while new
bone is formed at the site of the endochondral bone
growth plate. Another soluble factor used for
chondrogenic differentiation of MSCs is fibroblast
growth factor 2 (FGF-2). MSCs that have been
stimulated with FGF-2 in monolayer culture after being
transferred to a 3-dimensional environment, produce
more CSPG and cells with a round chondrogenic
phenotype (Solchaga et al., 2005a; Chiou et al., 2006).
Chondrogenic induction hereby seems to be mediated
via the MAPKinase signaling pathway (Murakami et al.,
2000). Treatment with FGF-2 has been shown to
significantly enhance Sox9 expression and that this is
mediated via the MAPKinase signal transduction
pathway (Murakami et al., 2000). It is well known that
the MAPKinase pathway plays a pivotal role in
differentiation, development of the chondrogenic
phenotype and specific function of chondrocytes
(Shakibaei and Merker, 1999; Shukunami et al., 2001). It
has recently been shown that ERK1/2 even physically
interacts with Sox9 (Shakibaei et al., 2006).
Mesenchymal stem cells and cartilage repair
The simplest approach of cartilage repair using
MSCs can be done analogous to the ACT method. After
expanding the MSCs in vitro they are injected into a
cartilage defect. MSCs are hereby frequently combined
with a soluble scaffold to ensure they remain in the
cartilage defect similar to the fibrin glue or the periosteal
flap used in classic ACT. The results have been
ambiguous. Some have reported the formation of new
cartilage, whereas others have shown degradation and
fragmentation of the MSCs. Most studies are still in the
experimental trial phase and have been performed using
animal models, such as rabbit (Im et al., 2001) and goat
(Quintavalla et al., 2002; Murphy et al., 2003). In
359
Mesenchymal stem cells for cartilage repair
Fig. 7. A. Electron microscopic demonstration of MSCs induced with chondrogenic medium in high-density culture. After 14 days nodules with typical
round or oval chondrocytes (C) with small processes embedded in a network of extracellular matrix fibrils (M) could be observed. These nodules, typical
for cartilage formation, were surrounded by a layer of flattened, fibroblast-like cells embedded in fibrils of thick extracellular matrix. x 5000. 
B. Transmission immunoelectron microscopic images of high-density MSC cultures induced with chondrogenic induction medium. Chondrogenic
induced cultures were immunogold labelled with anti-cartilage-specific proteoglycan antibodies. Anti-cartilage specific proteoglycan labelled gold
particles formed clusters which were distributed irregularly in the extracellular matrix (arrows). x 20,000
rabbits, positive results regarding new cartilage
formation have been reported after MSC administration
into the defect (Im et al., 2001). Here,
immunohistochemical staining of the newly formed
cartilage was more intense for type-II collagen in the
matrix and higher amounts of mRNA for type-II
collagen were detected compared to the control group. In
a study using goats subjected to total removal of the
medial meniscus, there was evidence of marked
regeneration of the medial meniscus after MSC
injection, as well as detection of the implanted cells in
the newly formed tissue (Murphy et al., 2003).
Furthermore, degeneration of the articular cartilage,
subchondral bone remodeling, osteophyte formation and
subchondral sclerosis were reduced in cell-treated joints
compared to joints treated with the vehicle alone.
Contrary to this, in another goat cartilage defect model,
two weeks post-implantation a gradual loss of implanted
cells in the defect as well as fragments of gelatin sponge
containing labelled MSC in deep marrow spaces was
observed, indicating fragmentation, dislodgement and
passive migration (Quintavalla et al., 2002). In other
studies MSCs have been implanted after differentiation
towards chondrocytes or on scaffolds with successful
formation of cartilage-like tissue in parts of the defect
(Wakitani et al., 1994; Meinel et al., 2004; Liu et al.,
2006).
Clinical trials of human patients undergoing cartilage
Repair with MSCs
Although a number of animal studies have been
performed using MSCs for articular cartilage repair,
until now only a few clinical trials have been performed
on human patients (Wakitani et al., 2002). This is, as
indicated above, mainly due to the varying results that
the treatment of cartilage defects with MSCs has
achieved in animal models. Recently however, a group
from Japan performed a study on 24 patients diagnosed
with OA (Wakitani et al., 2002). In this study,
autologous MSCs were obtained from the patients' bone
marrow and expanded in monolayer culture. After
obtaining sufficient cell numbers, MSCs were seeded
onto a collagen type I membrane and transplanted into
the cartilage defect. 12 patients served as the control
group and received cell free implants. Histological
evaluation of biopsies taken after two years showed
significantly higher hyaline cartilage formation in the
treated compared to the untreated group. However, there
was no way of tracking the implanted MSCs for this
long time period so it remains unclear whether the newly
formed tissue was consisting of the implanted MSCs.
Problems with tissue engineering cartilage from MSCs
MSCs may represent a useful cell source as an
alternative approach to the treatment of cartilage defects
due to their availability in relatively high numbers and
the easy ways to obtain them. However, a limiting factor
is that in the cartilage resulting from MSCs, markers
connected with hypertrophic chondrocyte differentiation
such as alkaline phosphatase and collagen type X are up-
regulated and growth factors are needed for
chondrogenic induction (Johnstone et al., 1998). MSCs
that differentiate towards the chondrogenic lineage in
vitro do not express a stable chondrogenic phenotype.
Collagen type X is considerably up-regulated in 3-
dimensional culture and detectable around day seven
with RT-PCR (Johnstone et al., 1998; Barry et al., 2001)
and around day 14 with immunohistochemistry (Yoo et
al., 1998). In healthy mature chondrocytes and in
engineered cartilage from mature chondrocytes, collagen
type X is either not present or is only marginally
expressed (Riesle et al., 1998; Tallheden et al., 2004;
Zhang et al., 2004). As collagen type X makes up 45%
of the collagen produced in hypertrophic chondrocytes,
it is considered an important marker of endochondral
bone formation (Gibson and Flint, 1985; Shen, 2005).
MSCs that differentiate towards the chondrogenic
lineage exhibit elevated levels of alkaline phosphatase
expression and activity. The induction of chondrogenesis
in MSCs is accompanied by an increase of alkaline
phosphatase activity around day 7 reaching a peak
around day 14. Contrary to this, in normal mature
articular chondrocytes from the superficial and the
middle zone of the joint surface, no alkaline phosphatase
activity can be detected. Alkaline phosphatase activity
has been described in hypertrophic chondrocytes in the
calcified zone, in endochondral ossification centers, the
growth plate and bone (Henson et al., 1995; Miao and
Scutt, 2002).
Conclusions and future perspectives
The ultimate goal of clinicians and scientists
involved in cartilage and OA research is achieving better
articular cartilage repair and eliminating or significantly
reducing pain and inflammation while restoring a
mechanically functional repair tissue. However, the
scientific and clinical evidence provided thus far
suggests that we are still a long way from being able to
create functionally competent hyaline cartilage with a
zonal architecture similar to that found in native articular
cartilage. Although the research done in the last two
decades has narrowed the gap to achieving this goal,
there is still a long way to go. Nevertheless, the pace of
progress has been significantly enhanced with the advent
of tissue engineering and stem cell technologies. No
matter which approach is favored, the outcome is still
and will remain a more effective and robust hyaline
cartilage repair. ACT has established itself in clinical
medicine and has become a widely accepted method for
treating cartilage defects in OA.
Tissue engineering is an integral part of regenerative
medicine that seeks to address the urgent need for
replacement tissues. The delivery of phenotypically
stable cells in 3-dimensional scaffolds to promote
healing for repair, replacement or regeneration of tissues
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is a key aspect of connective tissue engineering. The
seamless integration of basic biology and materials
engineering is a defining characteristic of tissue
engineering and regenerative medicine. However, it is
critical is that any bioengineered material has a 3-
dimensional structure that is designed to meet specific
physical requirements of the original tissue and promote
cell and tissue integration. This article has focused on
ACT, MSCs, cartilage tissue engineering and has
critically evaluated the strengths and limitations of
existing techniques for articular cartilage repair and
regeneration. Future studies will need to focus on the
intricacies of the unique cell biology of MSCs and the
biochemical signal transduction pathways involved in
maintaining and enhancing chondrogenic differentiation.
This knowledge will enable tissue engineers to create
more durable biomaterials capable of replacing cartilage
defects. Understanding the biology of MSCs and their
interaction with engineered 3-dimensional scaffolds will
enable a variety of connective tissues including cartilage,
bone, tendon and ligament to be generated in the
laboratory for applications in regenerative medicine and
autologous transplantation.
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